{"name":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","slug":"acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-inc-rahway-nj-usa","ticker":"","exchange":"","domain":"","description":"Acceleron Pharma, a wholly-owned subsidiary of Merck & Co., is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics to treat serious and rare diseases. The company has a robust pipeline with multiple drugs in various stages of clinical development.","hq":"","founded":0,"employees":"~700","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ACE-031","genericName":"ACE-031","slug":"ace-031","indication":"Muscular dystrophy","status":"phase_1"},{"name":"ACE-041","genericName":"ACE-041","slug":"ace-041","indication":"Other","status":"phase_1"},{"name":"ACE-536","genericName":"ACE-536","slug":"ace-536","indication":"Beta-thalassemia","status":"phase_3"}]}],"pipeline":[{"name":"ACE-031","genericName":"ACE-031","slug":"ace-031","phase":"phase_1","mechanism":"Activates the activin receptor type II-A (ActRIIA), leading to increased myostatin inhibition.","indications":["Muscular dystrophy","Muscle wasting"],"catalyst":""},{"name":"ACE-041","genericName":"ACE-041","slug":"ace-041","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ACE-536","genericName":"ACE-536","slug":"ace-536","phase":"phase_3","mechanism":"ACE-536 is an activin receptor ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.","indications":["Beta-thalassemia","Myelodysplastic syndromes (MDS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQZUdVWURucE1KWTRYeFg1Yzl5T1BtVERsY1BPUzFta1kzNmRUWFRhcVlUVFJmVmk0QUJxdHk1d3BRMFdYMzBKMjd6LUJ4cy0zVjZXMjhndXhic0d6MVJoWlRTc2lPcS1kWWU0dW03S1FidDNCcmo2dUx0WnViVUhTbWlSR24zeHZCR051TXllYzJxM1pOLURuNmtB?oc=5","date":"2026-02-25","type":"deal","source":"BioWorld News","summary":"Returning to pulmonary hypertension, GSK buys 35Pharma - BioWorld News","headline":"Returning to pulmonary hypertension, GSK buys 35Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPXzdraFpPbWM4bjdPMFFUZ1BTZ180OVNyaDgyX2phcThidDhZWnVFWHV6TkM0MmJNVklPdlhOeUFmaWJseVI2cjRoZ0RITnZ4MTBnYm0tdktUZ0NHcDJWTkdNMVFZMGc2clhkX3dwd0QwNk5iMlgybXYzLVZxNHhTT3BsZ0ZVa1NzTjFEdVZSNXpzbVpmZjhMemF2amk1SjJ1alVwXzdXZ1lzcGEzbEI3V0VlbXJNTF94SFU4Nmh3OGpEVWZPY1E?oc=5","date":"2025-02-11","type":"regulatory","source":"Pharmacy Times","summary":"Phase 3 HYPERION Trial Evaluating Sotatercept-Csrk Ends Prematurely, Moving to Final Analysis - Pharmacy Times","headline":"Phase 3 HYPERION Trial Evaluating Sotatercept-Csrk Ends Prematurely, Moving to Final Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBBeWgyR1RtQnUzT3FsbEFCSlA5U1ZuMFNNSzdmSlRZXzlIaUptWkZXNy1XSmh4a1F6WkdWM2dxS2I0bER5YjZLcU44dDNoeTd5Vm14ZF80V1RUdTJJLUZwTlc5NngxSFE4UUVsV01Lb1JrWUFz?oc=5","date":"2025-01-13","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2024 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9pbE83WHJXQmUxTXI3X1BLR0paVXM4bXNOeEpkdmxIblFlb1VaVjhaZ3hEaGxwZjJ6MndjTUxWMk0wbm9FMkRFVC1TQkxxZi1ocUFHZTgzRUtBYXc1UXhYUkM4YWxwRFYxQUVJejQyZXNNTzQ?oc=5","date":"2024-05-29","type":"pipeline","source":"Wiley","summary":"Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension - Wiley","headline":"Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hyperten","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1McGNvcnF1bGNjZml6cUV5SmJFcTVESE10MzNldHE1N0M1S1Nna0JrYWl4LVkzLTIzbGtvQmo5VGJaR3F4R3FnMnhtZDNpclk4QU1WNjVsNUp3LS1RcWpfeGxQUWJRcjlRNUE?oc=5","date":"2023-04-24","type":"trial","source":"Wiley Online Library","summary":"Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept - Wiley Online Library","headline":"Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOZi1uczNUeXhkd0lHamRWZVQzVnlwdnQzRU14SjRoazhrVzVNX1RtXzVxTGI1T3VSM0FsV3RqWXhYSU5tYXR6QzRxTXRhUUQxRDJ2cnJVekRIVmtZVThZN3hnUVZZaU5KNjZOQlhGdVdFaTMxaWRpbUdla2dRQldiX3I4RXZWN3pfZTFsUW1remZqalhoU21yeVlOcVJjTmJtUWc?oc=5","date":"2023-02-22","type":"pipeline","source":"Frontiers","summary":"Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure - Frontiers","headline":"Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUVd6QndRaDdON1MwbkV3bmxPY09vbFhERnVKbW5uZHJJR2loTXN0Vi05LWFGOThLbWpDdm5JUTlpUVM5RzB1QXcxOHpBUVc2SUNsTHVVMzFOM1FUdFBCeXBaYlloWVNQNHNrMHpxT1NRa29aVkxPS3hUX0lLaFNFRjBTS0NqcjY0T01sYkRkSkxHODZyVVQ4NDFvdw?oc=5","date":"2021-09-30","type":"deal","source":"Business Wire","summary":"Merck to Acquire Acceleron Pharma Inc. - Business Wire","headline":"Merck to Acquire Acceleron Pharma Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeFJTSnNRWHFVMFJJZzlibko4b0xsMHJPV1AyU1JCQmF4eEh1Rl9SZ2p0UGZscGg0WWtWR09xa0U2TXZaNnR5Z0NPaE1ibks2MWF3eHZaeG50VkNNS1JNd3RfaGdLUE1zazdHYjB0SFpZM2c1SlNuandJSnk1TlY4ME4xZDVQVEs2eGlfUGxqLTY0dmRXaUNHYXFTeVdvSXlCWU1jMGVNVktJUnE0UUozSjBYOXE2WkxJcDV0OHB5ZDFiYjBSX3VlMQ?oc=5","date":"2021-09-30","type":"deal","source":"Reuters","summary":"Merck to buy Acceleron for about $11.5 bln in rare disease drug push - Reuters","headline":"Merck to buy Acceleron for about $11.5 bln in rare disease drug push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiOkFVX3lxTE9xUnktMklHVURZci1jbkxlOUlJWXAwd0JFLXItcENtRDJlM3dINVJVZkV0S3BmeFVwcGc?oc=5","date":"2006-03-15","type":"pipeline","source":"Merck","summary":"Merck | Home - Merck","headline":"Merck | Home","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}